Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Morphic Holding (MORF)
NASDAQ:MORF
Morphic Holding (MORF) Stock Price & Analysis
243 Followers
MORF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$19.35 - $62.08
Previous Close$56.61
Volume1.41M
Average Volume (3M)2.14M
Market Cap
$2.84B
Enterprise Value$2.21B
Total Cash (Recent Filing)$628.37M
Total Debt (Recent Filing)$1.16M
Price to Earnings (P/E)―
Beta1.42
Next Earnings
Jul 31, 2024EPS Estimate
-$1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.60
Shares Outstanding50,093,588
10 Day Avg. Volume636,114
30 Day Avg. Volume2,140,729
Standard Deviation0.20
R-Squared0.15
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)2.15
Price to Sales (P/S)2737.36
Price to Cash Flow (P/CF)-7.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.24K
Enterprise Value/Ebitda-15.46
Forecast
1Y Price Target
$58.17Price Target Upside2.86% Upside
Rating ConsensusHold
Number of Analyst Covering9
Morphic Holding News
Bulls Say, Bears Say
Bulls Say
Market ConfidenceThe acquisition of MORF ahead of the topline readout from the Phase 2b EMERALD-2 study in UC speaks to LLY’s confidence in MORF-057’s clinical profile and the commercial opportunity for a safe and effective oral therapy in IBD.
Strategic FitThe MORF acquisition is a strong strategic fit for LLY, which can leverage their resources and expertise in clinical development and commercial experience/infrastructure in IBD to maximize the value of MORF-057.
Therapeutic PotentialThe convenience associated with the oral administration and the non-immunosuppressive feature of MORF-057 gives it the potential to become an obvious combination candidate.
Bears Say
AcquisitionThe risk of another buyer at this stage is low given the premium Lilly has offered, and board commentary that the company was not put up for sale.
Financial PerformanceThe position in the tx paradigm will be dependent on its final PBO-adjusted remission rate.
Stock RatingDowngrading shares of MORF to Market Perform following the announcement of Lilly's proposed acquisition.
---
Ownership Overview
35.07% Insiders
34.74% Mutual Funds
11.19% Other Institutional Investors
19.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MORF FAQ
What was Morphic Holding’s price range in the past 12 months?
Morphic Holding lowest stock price was $19.34 and its highest was $62.08 in the past 12 months.
What is Morphic Holding’s market cap?
Currently, no data Available
When is Morphic Holding’s upcoming earnings report date?
Morphic Holding’s upcoming earnings report date is Jul 31, 2024 which is in 4 days.
How were Morphic Holding’s earnings last quarter?
Morphic Holding released its earnings results on Apr 25, 2024. The company reported -$0.91 earnings per share for the quarter, beating the consensus estimate of -$0.941 by $0.031.
Is Morphic Holding overvalued?
According to Wall Street analysts Morphic Holding’s price is currently Undervalued.
Does Morphic Holding pay dividends?
Morphic Holding does not currently pay dividends.
What is Morphic Holding’s EPS estimate?
Morphic Holding’s EPS estimate is -$1.01.
How many shares outstanding does Morphic Holding have?
Morphic Holding has 50,100,693 shares outstanding.
What happened to Morphic Holding’s price movement after its last earnings report?
Morphic Holding reported an EPS of -$0.91 in its last earnings report, beating expectations of -$0.941. Following the earnings report the stock price went up 1.047%.
Which hedge fund is a major shareholder of Morphic Holding?
Among the largest hedge funds holding Morphic Holding’s share is Perceptive Advisors LLC. It holds Morphic Holding’s shares valued at 10M.
---
Morphic Holding Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$58.17 (2.86% Upside)
$58.17 (2.86% Upside)
Hedge Fund Trend
Increased
By 20.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 11.0%
Last 30 Days ▲ 11.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.03%
12-Months-Change
Fundamentals
Return on Equity
-26.68%
Trailing 12-Months
Asset Growth
-13.71%
Trailing 12-Months
Company Description
Morphic Holding
Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.
---
MORF Stock 12 Month Forecast
Average Price Target
$58.17
▲(2.86% Upside)
Technical Analysis
Best Analysts Covering MORF
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+24.55%
reiterated a buy rating 19 days ago
Copying Derek Archila's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +24.55% per trade.
---